Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications

被引:22
作者
Miele, Luca [1 ]
Targher, Giovanni [2 ]
机构
[1] Univ Cattolica Sacro Cuore, Liver Unit, Rome, Italy
[2] Univ Verona, Med, I-37126 Verona, Italy
关键词
cardiovascular disease; metabolic syndrome; NAFLD; NASH; Type; 2; diabetes; HEPATIC INSULIN-RESISTANCE; CORONARY-ARTERY-DISEASE; FOLLOW-UP; CARDIOVASCULAR-DISEASE; NAFLD; RISK; MORTALITY; BURDEN;
D O I
10.1586/17474124.2015.1074860
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries and is also predicted to become the most frequent indication for liver transplantation by 2030. In the last decade, it has become evident that the clinical burden of NAFLD is not restricted to liver-related morbidity or mortality, but there is now compelling evidence that NAFLD is a multisystem disease, affecting many extra-hepatic organs. In this article, we discuss the evidence linking NAFLD with important cardiometabolic complications (mainly Type 2 diabetes and cardiovascular disease) and the putative underlying mechanisms by which NAFLD may contribute to the development of these complications.
引用
收藏
页码:1243 / 1245
页数:3
相关论文
共 22 条
[1]   Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis [J].
Anstee, Quentin M. ;
Targher, Giovanni ;
Day, Christopher P. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (06) :330-344
[2]   Association between nonalcoholic fatty liver disease and coronary artery disease [J].
Arslan, Ugur ;
Tuerkoglu, Sedat ;
Balcioglu, Serhat ;
Tavil, Yusuf ;
Karakan, Tarkan ;
Cengel, Atiye .
CORONARY ARTERY DISEASE, 2007, 18 (06) :433-436
[3]   Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease [J].
Ballestri, Stefano ;
Lonardo, Amedeo ;
Bonapace, Stefano ;
Byrne, Christopher D. ;
Loria, Paola ;
Targher, Giovanni .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (07) :1724-1745
[4]   Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes [J].
Birkenfeld, Andreas L. ;
Shulman, Gerald I. .
HEPATOLOGY, 2014, 59 (02) :713-723
[5]   NAFLD: A multisystem disease [J].
Byrne, Christopher D. ;
Targher, Giovanni .
JOURNAL OF HEPATOLOGY, 2015, 62 :S47-S64
[6]   Long-term follow-up of patients with NAFLD and elevated liver enzymes [J].
Ekstedt, Mattias ;
Franzen, Lennart E. ;
Mathiesen, Ulrik L. ;
Thorelius, Lars ;
Holmqvist, Marika ;
Bodemar, Goran ;
Kechagias, Stergios .
HEPATOLOGY, 2006, 44 (04) :865-873
[7]   Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up [J].
Ekstedt, Mattias ;
Hagstrom, Hannes ;
Nasr, Patrik ;
Fredrikson, Mats ;
Stal, Per ;
Kechagias, Stergios ;
Hultcrantz, Rolf .
HEPATOLOGY, 2015, 61 (05) :1547-1554
[8]   Hepatic Steatosis as a Marker of Metabolic Dysfunction [J].
Fabbrini, Elisa ;
Magkos, Faidon .
NUTRIENTS, 2015, 7 (06) :4995-5019
[9]   Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States [J].
Kim, Donghee ;
Kim, W. Ray ;
Kim, Hwa Jung ;
Therneau, Terry M. .
HEPATOLOGY, 2013, 57 (04) :1357-1365
[10]   Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease [J].
Lonardo, Amedeo ;
Ballestri, Stefano ;
Targher, Giovanni ;
Loria, Paola .
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (05) :629-650